Roche (RHHBY) announced that its cobas 6800/8800 systems – two integrated and fully automated molecular testing systems for blood and plasma donor screening are commercially available in markets which ...
INDIANAPOLIS, Oct. 29 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. introduction of the cobas e 602 analyzer, the latest addition to the cobas® 8000 modular analyzer ...
New process allows labs to use same Pap test vial instead of transferring sample to new vial, thus simplifying workflow INDIANAPOLIS, June 26, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) ...
(RTTNews) - Biopharmaceutical company Roche Holding AG (RHHBY), announced on Tuesday that its cobas HPV test for use on the cobas 6800/8800 Systems has been awarded the World Health Organization (WHO) ...
Assay is a companion diagnostic for EGFR tyroskine kinase inhibitors. Roche’s cobas EGFR Mutation Test received a CE mark. The regulatory stamp means the test will be commercially available as a ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announces an expanded CE mark indication for the cobas® 4800 HPV Test. The newly expanded indication for the cobas® 4800 HPV Test as a primary screen means Pap ...
New cobas(R) 4800 System designed to increase laboratory efficiency and medical value Roche Diagnostics Canada (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new Health Canada approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback